The Zhitong Finance App learned that on July 21, 2026, Shanghai Xinwei Medical Technology Co., Ltd. (06609) announced the 2026 mid-term profit forecast. The company's revenue from January to June 2026 is expected to be no less than RMB 280 million, an increase of more than 50% over the same period in 2025; the net profit is expected to be no less than RMB 60 million; the adjusted net profit is expected to be no less than RMB 70 million, an increase of more than 100% over the same period in 2025, further improving profitability.
Revenue increased by more than 50% year on year, core business continued to break through, and growth momentum continued to be unleashed
During the reporting period, the company continued to promote the development of the three core businesses of ischemic stroke, hemorrhagic stroke and vascular closure. The clinical approval and market penetration rate of core products continued to increase, driving steady growth in terminal demand. At the same time, the company continues to expand the hospital coverage network, expand the scope of product application, and promote rapid growth in core business revenue.
Adjusted net profit increased by more than 100% year-on-year, profitability continued to improve, and operational efficiency continued to improve
During the reporting period, the company continued to upgrade its business structure, moving from phase 1.0 driven by channel products to phase 2.0 led by innovative therapeutic products. The revenue contribution of high-value innovative products continued to increase, driving an improvement in overall gross margin compared to the same period last year. At the same time, the company continues to strengthen refined operation management, improve resource allocation efficiency, and achieve a rapid increase in adjusted net profit.
The rapid growth in business performance is an important achievement of Xinwei Medical consolidating technical capabilities, optimizing product structure, and improving operational quality. It reflects the continuous improvement of the company's business quality and development resilience. Looking forward to the future, Xinwei Medical will continue to focus on clinical needs in the field of neurological intervention, adhere to innovation-driven development, accelerate the commercialization process of innovative products, continuously improve R&D innovation and market expansion capabilities, promote clinical application of more innovative medical devices, and create long-term and sustainable value for shareholders and society.